Radiofrequency ablation and surgical resection of liver metastases from uveal melanoma

Mariani, Pascale; Almubarak, Maher Mohamed; Kollen, M.H.; Wagner, Mathilde; Plancher, Corine; Audollent, R.; Piperno‐Neumann, Sophie; Cassoux, Nathalie; Servois, Vincent

doi:10.1016/j.ejso.2016.02.019

Cited by 50 publications

(37 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The largest four studies, each with ≥ 40 patients who underwent liver resection for liver metastases from melanoma, reported an overall 5-year survival rate of approximately 7%-20% with a median survival time of 14-28 mo (Table 7 )[ 10 , 44 - 46 ]. Short disease-free interval from the diagnosis of primary tumor[ 45 ], positive resection margin[ 45 ], > 4 liver metastases[ 45 ], miliary disease of the primary melanoma[ 45 ], cutaneous melanoma[ 46 ], and no preoperative chemotherapy were the risk factors predicting poor patients survival (Table 7 ). The metastatic pathway of ocular and cutaneous melanomas is different.…”

Section: Liver Metastases From Melanomamentioning

confidence: 99%

Role of surgical resection for non-colorectal non-neuroendocrine liver metastases

Takemura

Saiura

2017

WJH

View full text Add to dashboard Cite

It is widely accepted that the indications for hepatectomy in colorectal cancer liver metastases and liver metastases of neuro-endocrine tumors result in relatively better prognoses, whereas, the indications and prognoses of hepatectomy for non-colorectal non-neuroendocrine liver metastases (NCNNLM) remain controversial owing to the limited number of cases and the heterogeneity of the primary diseases. There have been many publications on NCNNLM; however, its background heterogeneity makes it difficult to reach a specific conclusion. This heterogeneous disease group should be discussed in the order from its general to specific aspect. The present review paper describes the general prognosis and risk factors associated with NCNNLM while specifically focusing on the liver metastases of each primary disease. A multidisciplinary approach that takes into consideration appropriate timing for hepatectomy combined with chemotherapy may prolong survival and/or contribute to the improvement of the quality of life while giving respite from systemic chemotherapy.

show abstract

Section: Liver Metastases From Melanomamentioning

confidence: 99%

Role of surgical resection for non-colorectal non-neuroendocrine liver metastases

Takemura

Saiura

2017

WJH

View full text Add to dashboard Cite

show abstract

“…The mean tumor size for those treated with RFA was 13.5 mm (range: 3-25 mm). 122 In another review of 32 patients who underwent surgical resection and 16 patients who underwent percutaneous thermal ablation, median OS was 26 and 18 months, respectively (p > 0.2). Patients in the ablation group were more likely to have extrahepatic disease and to have received systemic chemotherapy prior to intervention.…”

Section: Thermal Ablation Of Metastatic For Uveal Melanomamentioning

confidence: 98%

Metastatic Liver Disease: Indications for Locoregional Therapy and Supporting Data

Shamimi-Noori

Gonsalves

Shaw

2017

Semin intervent Radiol

View full text Add to dashboard Cite

Metastatic liver disease is a major cause of cancer-related morbidity and mortality. Surgical resection is considered the only curative treatment, yet only a minority is eligible. Patients who present with unresectable disease are treated with systemic agents and/or locoregional therapies. The latter include thermal ablation and catheter-based transarterial interventions. Thermal ablation is reserved for those with limited tumor burden. It is used to downstage the disease to enable curative surgical resection, as an adjunct to surgery, or in select patients it is potentially curative. Transarterial therapies are indicated in those with more diffuse disease. The goals of care are to palliate symptoms and prolong survival. The indications and supporting data for thermal ablation and transarterial interventions are reviewed, technical and tumor factors that need to be considered prior to intervention are outlined, and finally several cases are presented.

show abstract

“…Confirming rates were reported in several noncomparative studies [ 176 , 182 , 183 , 184 , 185 , 186 ]. Other studies evaluated RFA or hepatic intra-arterial chemotherapy (HIA) as an adjunct to liver surgery to increase the number of patients with bilobar metastases achieving R0 resection [ 181 , 187 , 188 ]. Importantly, RFA associated with liver surgery and liver surgery alone demonstrated similar survival outcomes [ 187 ].…”

Section: Treatment Of Metastatic Diseasementioning

confidence: 99%

“…Other studies evaluated RFA or hepatic intra-arterial chemotherapy (HIA) as an adjunct to liver surgery to increase the number of patients with bilobar metastases achieving R0 resection [ 181 , 187 , 188 ]. Importantly, RFA associated with liver surgery and liver surgery alone demonstrated similar survival outcomes [ 187 ]. In addition, a recent study evaluated combined surgery and RFA in a small group of patients relapsing after complete first liver resection, showing prolonged survival outcomes [ 189 ].…”

Section: Treatment Of Metastatic Diseasementioning

confidence: 99%

Molecular Insights and Emerging Strategies for Treatment of Metastatic Uveal Melanoma

Mallone

Sacchetti

Moramarco

2020

Cancers

View full text Add to dashboard Cite

Uveal melanoma (UM) is the most common intraocular cancer. In recent decades, major advances have been achieved in the diagnosis and prognosis of UM allowing for tailored treatments. However, nearly 50% of patients still develop metastatic disease with survival rates of less than 1 year. There is currently no standard of adjuvant and metastatic treatment in UM, and available therapies are ineffective resulting from cutaneous melanoma protocols. Advances and novel treatment options including liver-directed therapies, immunotherapy, and targeted-therapy have been investigated in UM-dedicated clinical trials on single compounds or combinational therapies, with promising results. Therapies aimed at prolonging or targeting metastatic tumor dormancy provided encouraging results in other cancers, and need to be explored in UM. In this review, the latest progress in the diagnosis, prognosis, and treatment of UM in adjuvant and metastatic settings are discussed. In addition, novel insights into tumor genetics, biology and immunology, and the mechanisms underlying metastatic dormancy are discussed. As evident from the numerous studies discussed in this review, the increasing knowledge of this disease and the promising results from testing of novel individualized therapies could offer future perspectives for translating in clinical use.

show abstract

Radiofrequency ablation and surgical resection of liver metastases from uveal melanoma

Cited by 50 publications

References 22 publications

Role of surgical resection for non-colorectal non-neuroendocrine liver metastases

Role of surgical resection for non-colorectal non-neuroendocrine liver metastases

Metastatic Liver Disease: Indications for Locoregional Therapy and Supporting Data

Molecular Insights and Emerging Strategies for Treatment of Metastatic Uveal Melanoma

Contact Info

Product

Resources

About